MYOK News and Press, MyoKardia Inc. From 11/04/19

MyoKardia (NASDAQ: MYOK ): Q3 GAAP EPS of -$3.07 misses by $1.06 . More news on: MyoKardia, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the quarter ended September 30, 2019. “As we look across the milestones recently achieved and those just ahead, we see steady progress on our near- a...

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA) Scientific Sessions taking place November 16 – November 18, 2019 in Philadelphia, Penn...

MyoKardia ( MYOK -0.5% ) announces positive preliminary data from a Phase 2a clinical trial evaluating MYK-491 in patients with stable heart failure due to the inability of the left ventricle to pump blood effectively. More news on: MyoKardia, Inc., Healthcare stocks news, Read m...

Interim Data Demonstrated Favorable Safety and Activity Profile in Phase 2a Multiple-Ascending Dose Study Phase 2 Clinical Trial in Targeted Segment of Genetic DCM to Initiate in 1H 2020 SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), ...

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019, at 4:10 p.m. ET in N...

MKM partners initiates coverage on seven pot stocks: Curaleaf Holdings ( OTCPK:CURLF ): Sell, Aurora Cannabis (NYSE: ACB ): Sell ( -1% ), Canopy Growth (NYSE: CGC ): Neutral (up a fraction), Tilray (NASDAQ: TLRY ): Neutral (up a fraction), Cronos Group (NASDAQ: CRON ): Neutral ( +1% ), ...

The following slide deck was published by MyoKardia, Inc. in conjunction with this Read more ...

MyoKardia ( MYOK -1.2% ) plans to launch a study in H1 2020 evaluating lead drug mavacamten as an alternative to septal reduction therapy (SRT) in patients with obstructive hypertrophic cardiomyopathy (HCM), a disorder in which the heart muscle becomes abnormally thick making it harder f...

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy (SRT). The study will be conducted at leading HCM centers that regularly perform surgical my...